Baicalein tethers CD274/PD-L1 for autophagic degradation to boost antitumor immunity

被引:0
|
作者
Hao, Bingjie [1 ,2 ]
Lin, Shumeng [1 ,2 ]
Liu, Haipeng [3 ]
Xu, Junfang [3 ]
Chen, Li [3 ]
Zheng, Tiansheng [2 ]
Zhang, Wen [2 ]
Dang, Yifang [4 ]
Reiter, Russel J. [5 ]
Li, Chaoqun [1 ]
Zhai, Hong [2 ]
Xia, Qing [1 ]
Fan, Lihong [1 ,2 ,6 ]
机构
[1] Tongji Univ, Shanghai Peoples Hosp 10, Inst Energy Metab & Hlth, Sch Med, Shanghai, Peoples R China
[2] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Resp Med, Shanghai 200072, Peoples R China
[3] Tongji Univ, Shanghai Pulm Hosp, Clin Translat Res Ctr, Sch Med, Shanghai, Peoples R China
[4] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Shanghai, Peoples R China
[5] Univ Texas Hlth San Antonio, Dept Cell Syst & Anat, San Antonio, TX USA
[6] Shanghai Jiao Tong Univ, Sch Med, Dept Resp Med, Shanghai Peoples Hosp 6, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Antitumor immunity; autophagy; baicalein; CD274; MAP1LC3B; protein degradation; LYSOSOMAL DEGRADATION; PD-L1; ANTI-PD-1; BLOCKADE; PROTEINS; COMPLEX; TARGET;
D O I
10.1080/15548627.2024.2439657
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Immune checkpoint inhibitors, especially those targeting CD274/PD-L1yield powerful clinical therapeutic efficacy. Thoughmuch progress has been made in the development of antibody-basedCD274 drugs, chemical compounds applied for CD274degradation remain largely unavailable. Herein,baicalein, a monomer of traditional Chinese medicine, isscreened and validated to target CD274 and induces itsmacroautophagic/autophagic degradation. Moreover, we demonstrate thatCD274 directly interacts with MAP1LC3B (microtubule associatedprotein 1 light chain 3 beta). Intriguingly, baicalein potentiatesCD274-LC3 interaction to facilitate autophagic-lysosomal degradationof CD274. Importantly, targeted CD274. degradation via baicaleininhibits tumor development by boosting T-cell-mediated antitumorimmunity. Thus, we elucidate a critical role of autophagy-lysosomalpathway in mediating CD274 degradation, and conceptually demonstratethat the design of a molecular "glue" that tethers the CD274-LC3interaction is an appealing strategy to develop CD274 inhibitors incancer therapy.Abbreviations: ATTECs: autophagy-tethering compounds; AUTACs: AUtophagy-TArgeting Chimeras; AUTOTACs: AUTOphagy-TArgeting Chimeras; AMPK: adenosine 5'-monophosphate (AMP)-activated protein kinase; BiFC: bimolecular fluorescence complementation; BafA1: bafilomycin A1; CD274/PD-L1/B7-H1: CD274 molecule; CQ: chloroquine; CGAS: cyclic GMP-AMP synthase; DAPI: 4'6-diamino-2-phenylindole; FITC: fluorescein isothiocyanate isomer; GFP: green fluorescent protein; GZMB: granzyme B; IHC: immunohistochemistry; ICB: immune checkpoint blockade; KO: knockout; KD: equilibrium dissociation constant; LYTAC: LYsosome-TArgeting Chimera; LIR: LC3-interacting region; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MST: microscale thermophoresis; NFAT: nuclear factor of activated T cells; NFKB/NF-kB: nuclear factor kappa B; NSCLC: non-small-cell lung cancer; PDCD1: programmed cell death 1; PROTACs: PROteolysis TArgeting Chimeras; PRF1: perforin 1; PE: phosphatidylethanolamine; PHA: phytohemagglutinin; PMA: phorbol 12-myristate 13-acetate; STAT: signal transducer and activator of transcription; SPR: surface plasmon resonance; TILs: tumor-infiltrating lymphocyte; TME: tumor microenvironment.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD-L1 (CD274)-expression: Possible roles of tumour micro environmental factors for CD274 expression
    Inaguma, Shingo
    Lasota, Jerzy
    Felisiak-Golabek, Anna
    Kowalik, Artur
    Wang, Zengfeng
    Zieba, Sebastian
    Kalisz, Joanna
    Ikeda, Hiroshi
    Miettinen, Markku
    JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2017, 3 (04): : 268 - 278
  • [22] Clinical significance of PD-L1 (CD274) enhanced expression in cervical squamous cell carcinoma
    Feng, Min
    Xu, Lian
    He, Ying
    Sun, Liang
    Zhang, Yan
    Wang, Wei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2018, 11 (11): : 5370 - 5378
  • [23] CD274 (PD-L1) genomic change: another marker for small cell lung cancer?
    Inoue, Yusuke
    Suda, Takafumi
    Sugimura, Haruhiko
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S33 - S35
  • [24] CD274 (PD-L1) negatively regulates M1 macrophage polarization in ALI/ARDS
    Tang, Nana
    Yang, Yang
    Xie, Yifei
    Yang, Guohui
    Wang, Qin
    Li, Chang
    Liu, Zeyi
    Huang, Jian-an
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [25] TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells
    Boes, Marianne
    Meyer-Wentrup, Friederike
    CANCER LETTERS, 2015, 361 (01) : 49 - 56
  • [26] Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer
    Yang, Lin
    Liu, Shousheng
    He, Wenzhuo
    Xiong, Zhenchong
    Xia, Liangping
    BMC CANCER, 2023, 23 (01)
  • [27] Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses
    Starke, Astrid
    Lindenmeyer, Maja T.
    Segerer, Stephan
    Neusser, Matthias A.
    Ruesi, Barbara
    Schmid, Daniel M.
    Cohen, Clemens D.
    Wuethrich, Rudolf P.
    Fehr, Thomas
    Waeckerle-Men, Ying
    KIDNEY INTERNATIONAL, 2010, 78 (01) : 38 - 47
  • [28] The blockage signal for PD-L1/CD274 gene variants and their potential impact on lung carcinoma susceptibility
    Sakran, Mohamed I.
    Alalawy, Adel I.
    Alharbi, Amnah A.
    El-Hefnawy, Mohamed E.
    Alzahrani, Salem M.
    Alfuraydi, Ahmed
    Alzuaibr, Fahad Mohammed
    Zidan, Nahla S.
    Elsaid, Afaf M.
    Toraih, Eman A.
    Elshazli, Rami M.
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 125
  • [29] Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer
    Lin Yang
    Shousheng Liu
    Wenzhuo He
    Zhenchong Xiong
    Liangping Xia
    BMC Cancer, 23
  • [30] Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells
    Ke, Mengyun
    Zhang, Zhenhai
    Xu, Biyi
    Zhao, Shidi
    Ding, Yiming
    Wu, Xiaoning
    Wu, Rongqian
    Lv, Yi
    Dong, Jian
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 75